HROW — Harrow Health, Inc.

Harrow Health, Inc. (HROW) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 2025 Revenue: $89.1 million, a 33% year-over-year increase.
• Full Year 2025 Revenue: $272 million, up 36% from 2024.
• Adjusted EBITDA: $24.2 million for Q4 and $61.9 million for the full year, reflecting a 54% year-over-year growth.
• Cash from Operations: Approximately $44 million, ending the year with $72.9 million in cash and cash equivalents.

2. Strategic Updates and Business Highlights

• Harrow Health has significantly expanded its portfolio, acquiring over 15 branded ophthalmic products, establishing itself as a major player in the U.S. ophthalmic market.
• VEVYE: Positioned for revenue acceleration with expanded payer coverage and a plan to double the sales force, aiming for it to become a nine-figure revenue product in 2026.
• IHEEZO: Achieved record revenue driven by increased adoption among retina specialists, with expectations for price improvements and expanded market presence in 2026.
• TRIESENCE: Strong quarterly performance with a 193% increase in annual revenue, plans to double the sales force to enhance market penetration.
• Rare Specialty and Compounded Products: New leadership and resources aimed at unlocking value from this portfolio, with upcoming coding decisions expected to positively impact revenue.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected between $350 million and $365 million, with Q1 anticipated to be the lowest revenue quarter due to inventory adjustments and seasonal factors.
• Adjusted EBITDA Guidance: Projected between $80 million and $100 million for the full year, with stronger performance expected in the second half.
• Anticipation of continued growth in IHEEZO and VEVYE, alongside the launches of BYOOVIZ and BYQLOVI, which are expected to further enhance revenue streams.

4. Bad News, Challenges, or Points of Concern

• First Quarter Challenges: Anticipated lower revenue due to inventory drawdowns and the expiration of IHEEZO's ASC pass-through status, which could impact unit demand.
• Market Competition: Increased competition in the dry eye market and potential challenges in achieving market share against established players.
• Operational Risks: Dependence on successful execution of new product launches and clinical trials, particularly for G-MELT and YOCHIL, which are critical for future growth.

5. Notable Q&A Insights

• VEVYE Sales Dynamics: The sales force expansion aims to capture both new-to-brand patients and those previously paying cash, with a focus on increasing market share.
• Market Penetration Strategy: Emphasis on leveraging existing relationships and comprehensive offerings to differentiate from competitors in the biosimilar market.
• Clinical Data Importance: Upcoming studies for IHEEZO are expected to provide critical data that could drive adoption and enhance its market position.
• Operational Efficiency: Management is focused on maintaining profitability while increasing investments in sales and marketing to support growth.

Overall, Harrow Health, Inc. demonstrated strong financial performance in 2025, with a clear strategy for growth and expansion in the ophthalmic market, despite facing some near-term challenges and competitive pressures.